- Home
- NCZ vs VNDA Comparison
NCZ vs VNDA Comparison
Compare NCZ & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCZ
- VNDA
- Stock Information
- Founded
- NCZ 2003
- VNDA 2002
- Country
- NCZ United States
- VNDA United States
- Employees
- NCZ N/A
- VNDA N/A
- Industry
- NCZ Finance Companies
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- NCZ Finance
- VNDA Health Care
- Exchange
- NCZ Nasdaq
- VNDA Nasdaq
- Market Cap
- NCZ 228.3M
- VNDA 249.4M
- IPO Year
- NCZ N/A
- VNDA 2006
- Fundamental
- Price
- NCZ $13.84
- VNDA $4.38
- Analyst Decision
- NCZ
- VNDA Strong Buy
- Analyst Count
- NCZ 0
- VNDA 2
- Target Price
- NCZ N/A
- VNDA $16.50
- AVG Volume (30 Days)
- NCZ 533.0K
- VNDA 388.7K
- Earning Date
- NCZ 01-01-0001
- VNDA 11-05-2025
- Dividend Yield
- NCZ 12.16%
- VNDA N/A
- EPS Growth
- NCZ N/A
- VNDA N/A
- EPS
- NCZ N/A
- VNDA N/A
- Revenue
- NCZ N/A
- VNDA $203,467,000.00
- Revenue This Year
- NCZ N/A
- VNDA $15.45
- Revenue Next Year
- NCZ N/A
- VNDA $37.82
- P/E Ratio
- NCZ N/A
- VNDA N/A
- Revenue Growth
- NCZ N/A
- VNDA 11.78
- 52 Week Low
- NCZ $2.50
- VNDA $3.81
- 52 Week High
- NCZ $3.15
- VNDA $5.55
- Technical
- Relative Strength Index (RSI)
- NCZ 70.85
- VNDA 41.13
- Support Level
- NCZ $13.70
- VNDA $4.54
- Resistance Level
- NCZ $13.94
- VNDA $4.64
- Average True Range (ATR)
- NCZ 0.09
- VNDA 0.15
- MACD
- NCZ 0.02
- VNDA -0.02
- Stochastic Oscillator
- NCZ 83.05
- VNDA 0.00
About NCZ Virtus Convertible & Income Fund II of Beneficial Interest
Virtus Convertible & Income Fund II is a diversified, closed-end management investment company. The investment objective of the company is to provide total return through a combination of capital appreciation and high current income. Its portfolio of investments includes different sector investments such as in healthcare services, media, oil, gas, and consumable fuels and others.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.